Two new collaborations show how the pharmaceutical industry is leaning on artificial intelligence to speed up the hunt for new medicines.
According to a report on Yahoo Finance, the company Evogene and Tel Aviv University's Blavatnik Center for Drug Discovery (BCDD) have announced a partnership aimed at expediting small-molecule drug discovery. Small molecules are the compounds behind most conventional pills, and finding promising ones is traditionally slow, expensive work — the kind of bottleneck AI is increasingly being pointed at.
Separately, according to simplywall.st, the analytics firm Certara has entered a partnership involving NVIDIA's BioNeMo platform, a development the outlet framed in terms of what it means for the company's shareholders. BioNeMo is Nvidia's toolkit built specifically for applying AI to biology and drug research.
Together, the two announcements point to a broader pattern: rather than building every capability in-house, drug developers are pairing with academic centers and technology providers that supply specialized AI infrastructure. Evogene is turning to a university drug-discovery center for scientific depth, while Certara is tapping Nvidia's computing platform for the raw AI horsepower.
The specific financial terms, timelines, and scientific targets were not detailed in the source items.
Why it matters: bringing a single drug to market can take many years, so even incremental speed-ups from AI partnerships could shape which treatments reach patients — and how quickly.